Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Genelux Corporation

In a report released today, Chad Messer from Lake Street maintained a Buy rating on Genelux Corp., with a price target of $16.00. According to TipR...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GNLX	$4.31	-2.05%	102.15K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GNLX	$4.31	-2.0%	102.15K
3
4
5
6

GNLX

GNLX

Dividend Overview

Get Genelux Corporation Data in Excel

Get Genelux Corporation Data in Excel